Online inquiry

IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2132MR)

This product GTTS-WQ2132MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2132MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9158MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ2597MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ5800MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ10746MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ13029MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ6901MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ3604MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ15917MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XOMA 052
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW